Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax ...

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Tenax Therapeutics (TENX – Research Report), with a price target of $30.00. See what stocks are receiving ...

(RTTNews) - Tenax Therapeutics, Inc. (TENX) announced an expansion of its Phase 3 LEVEL program for TNX-103 or oral levosimendan, a novel treatment for pulmonary hypertension with heart failure ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

These contain Phormium Tenax (New Zealand Flax) which are indestructible and can survive in almost any position and are grown for their long aching foliage. But they are rather inappropriate (to ...